Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

The SAPIEN 3 Ultra (S3U) transcatheter heart valve from Edwards Lifesciences is

Next-generation TAVR valve delivers strong outcomes, reduced PVL after one year

A team of specialists examined new outcomes data related to the SAPIEN 3 Ultra transcatheter heart valve, sharing its findings in EuroIntervention.

Shockwave L6 Peripheral IVL Catheter Shockwave Medical

Shockwave Medical launches new IVL catheter for challenging lesions in US

After its initial release was limited to certain customers, the new-look catheter is now available in four different sizes throughout the United States.

Nurse checking in patient

Structural heart clinics see key benefits from improved referral tracking

Sponsored by Medtronic

Identifying patients with severe aortic stenosis who could potentially benefit from transcatheter aortic valve replacement (TAVR) is very important—but managing and tracking them over time can be quite a challenge.

Doctor at computer

Data mining helps hospitals identify new patients in need of TAVR, other structural heart procedures

Sponsored by Medtronic

When the ACC and AHA collaborated on new valvular heart disease guidelines in 2020, the two groups highlighted the importance of interventional treatment options such as TAVR. However, an estimated one-third of patients with severe aortic stenosis in the U.S. still lack a guideline-recommended treatment plan.

Paul Sorajja, MD, director, Center for Valve and Structural Heart Disease, Minneapolis Heart Institute, Abbott Northwestern Hospital, was the principal investigator for the late-breaking TRILUMINATE pivotal trial at the American College of Cardiology (ACC) 2023 meeting and explains details of this landmark trial. #ACC #ACC23 #triluminate

TRILUMINATE trial may pave the way for FDA clearance for tricuspid valve clip device

Paul Sorajja, MD, discusses the late-breaking TRILUMINATE pivotal trial at ACC.23 and how tricuspid TEER performed against the current standard of care using medical therapy.

Links to all the American College of Cardiology late-breaking studies for ACC.23

Here are links to more information on every late-breaking presentation at ACC.23.

ACC 2023 program chair Douglas Drachman, MD, explains the top takeaways from the American College of Cardiology meeting. #ACC #ACC23

Key takeaways from the ACC 2023 annual meeting

ACC.23 Program Chair Doug Drachman, MD, explains what he saw as some of the key takeaways from the American College of Cardiology (ACC) 2023 annual meeting.

Thumbnail

What new data tell us about TAVR in women with a history of early menopause

Researchers examined data from more than 700 TAVR patients, publishing their findings in the American Journal of Cardiology.

Around the web

One of the most formidable societies of medical professionals in the U.S. is going toe-to-toe with Robert F. Kennedy’s HHS over changing vaccination recommendations. 

Tom Price, MD, former secretary of Health and Human Services (HHS), said one way to address the growing shortage of physicians is to expand medical resident positions, but these are tied to Medicare spending so alternative means may be needed.